SCHEMBL2084688

SCHEMBL2084688

CC(C)(NC(CCCN)Cc1nc2ccccc2[nH]1)c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.46
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
LMNA P02545 1/20 0.39
DDAH1 O94760 1/20 0.38
POLB P06746 1/20 0.38
PKM P14618 1/20 0.38
KDM4E B2RXH2 1/20 0.37
PIN1 Q13526 1/20 0.37
MAPK1 P28482 2/20 0.36
ALPL P05186 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 1/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2083640 0.77 CXCR4 (0.52) CXCR4RAB9ANPC1LMNADDAH1
SCHEMBL2085384 0.73 CXCR4 (0.43) CXCR4DDAH1POLBPKMKDM4E
SCHEMBL2084352 0.72 CXCR4 (0.45) CXCR4LMNAKDM4ECYP2D6CYP2C19
SCHEMBL2082170 0.71 CXCR4 (0.46) CXCR4RAB9ANPC1LMNADDAH1
SCHEMBL12935351 0.71 CXCR4 (0.59) CXCR4RAB9ANPC1LMNADDAH1
SCHEMBL2085996 0.70 CXCR4 (0.42) CXCR4RAB9ANPC1LMNADDAH1
SCHEMBL5112757 0.69 CXCR4 (0.58) CXCR4CYP2D6
SCHEMBL4759597 0.69 CXCR4 (0.58) CXCR4CYP2D6
SCHEMBL2504694 0.69 CXCR4 (0.58) CXCR4CYP2D6
SCHEMBL5107261 0.69 CXCR4 (0.58) CXCR4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US claimed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US claimed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US claimed
EP-1613613-B1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORP (US) 2021-06-02 EP disclosed
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 CXCR4 1/4885RAB9A 983/4885NPC1 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.